O
OVAX
Fentanyl vaccine technologies to prevent overdoses, focusing on prediction, prevention, and protection
About OVAX
OVAX is at the forefront of developing vaccine technologies aimed at combating the fentanyl crisis by preventing overdoses before they occur. The company targets the healthcare sector, specifically addressing the needs of individuals at risk of opioid addiction and overdose. OVAX operates within the pharmaceutical and biotechnology markets, leveraging scientific research and innovation to create solutions that save lives. The business model revolves around the development and potential commercialization of vaccines, such as the OVAX 100 and OVAX 200, which are designed to block the effects of fentanyl. Revenue generation is anticipated through partnerships, licensing agreements, and direct sales to healthcare providers and government entities. The company's mission is underscored by a commitment to public health and safety, with a focus on prediction, prevention, and protection against opioid-related harm.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- New York City, United States
- Employees
- 19
- Open positions
- 1
- Dealroom signal
- 83.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Addiction, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Jun 2026 | $0 | — | SRx Health Solutions | ↗ |
| EARLY VCOther financing | Jun 2024 | $10M | $40M | Undisclosed | — |
Growth signals
Latest recorded traffic for OVAX is 3.4K monthly website visits, down 20.9% over the last three months. OVAX's team grew 18.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
SRx Health Solutions
Other known investors2 additional known investors
Children’s Hospital Boston
Daft Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about OVAX on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OVAX’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.